Adding Necitumumab to Standard of Care Improves Survival in Squamous NSCLC
June 11th 2014Adding necitumumab to standard of care with gemcitabine-cisplatin improves survival compared with chemotherapy alone as first-line treatment in patients with stage IV non–small cell lung cancer (NSCLC) of squamous histology.
Read More
Panobinostat Combination Delays Disease Progression in Myeloma
June 11th 2014Combining the pan-deacetylase inhibitor panobinostat with bortezomib and dexamethasone delayed disease progression by 3.9 months over bortezomib and dexamethasone alone in patients with relapsed or relapsed and refractory multiple myeloma.
Read More
CD38-Specific Monoclonal Antibody Demonstrates Encouraging Efficacy in Myeloma
June 9th 2014SAR650984 demonstrated encouraging efficacy as a monotherapy and in combination with dexamethasone and lenalidomide without reaching a maximum tolerated dose in patients with heavily pretreated multiple myeloma.
Read More
Addition of ‘Smart’ Alkylator TH-302 to Dexamethasone Shows Benefit in Myeloma
June 6th 2014The addition of the investigational hypoxia-targeted drug TH-302 to dexamethasone has demonstrated beneficial activity and a manageable adverse event profile in the treatment of patients with relapsed/refractory multiple myeloma.
Read More
Joint Analysis of Phase III Trials Will Change Practice in Premenopausal HR+ Breast Cancer
June 3rd 2014A joint analysis of two phase III trials involving a total of 4690 premenopausal women with HR+ breast cancer demonstrated that adjuvant use of exemestane reduced relative risk of developing subsequent invasive cancer by 28% compared with tamoxifen.
Read More
14-Month Survival Benefit Demonstrated With Adding Chemo to ADT in Prostate Cancer
June 3rd 2014In what was described as “an almost unprecedented improvement in median survival,†the addition of the chemotherapy drug docetaxel to standard hormone therapy prolonged life for men with newly diagnosed metastatic, hormone-sensitive prostate cancer by nearly 14 months.
Read More
Comparing Toxicities and Patient-Stated Preference in the SWOG S0307 Trial
June 3rd 2014Julie R. Gralow, MD, discusses an analysis of the phase III SWOG S0307 trial comparing toxicities and patient-stated preference for oral versus intravenous delivery of bisphosphonates as adjuvant therapy in primary breast cancer.
Read More
Sirolimus and Vorinostat in Heavily Pretreated Refractory Hodgkin Lymphoma
June 2nd 2014Filip Janku, MD, PhD, discusses a trial presented at the 2014 ASCO Annual Meeting looking at the activity of the mTOR inhibitor sirolimus and HDAC inhibitor vorinostat in heavily pretreated patients with refractory Hodgkin lymphoma.
Read More
Bevacizumab, Cetuximab Equally Effective in <em>KRAS</em> Wild-Type mCRC
June 2nd 2014Frontline therapy with bevacizumab (Avastin) or cetuximab (Erbitux) combined with either FOLFOX or FOLFIRI yielded a comparable survival benefit of approximately 29 months in patients with <em>KRAS</em> wild-type metastatic colorectal cancer (mCRC).
Read More
Dual HER2-Blockade Strategy With Lapatinib Fails in ALTTO Trial
June 2nd 2014A dual HER2-blockade strategy that added lapatinib to trastuzumab for the adjuvant treatment of women with early breast cancer failed to demonstrate a significant improvement in disease-free survival (DFS) over the standard therapy with trastuzumab alone.
Read More
Promise Seen With EGFR Inhibitor CO-1686 in Treatment-Resistant NSCLC
June 2nd 2014The third-generation EGFR inhibitor CO-1686 continues to demonstrate promising activity in patients with non–small cell lung cancer (NSCLC) who developed resistance after prior treatment with an EGFR tyrosine kinase inhibitor (TKI).
Read More
Effect of Ziv-Aflibercept in the Bevacizumab Pre-Treated Subgroup of Patients in VELOUR
June 1st 2014Paulo Marcelo Hoff, MD, PhD, FACP, discusses a trial that looked at the consistency of effect of ziv-aflibercept in the bevacizumab pre-treated subgroup of patients in the VELOUR trial stratified by first-line progression ≥ 9 months versus < 9 months.
Read More
Ibrutinib Dramatically Increases PFS, OS in Phase III CLL Study
June 1st 2014Treatment with single-agent ibrutinib (Imbruvica) dramatically increased progression-free survival (PFS) by nearly 80% and significantly extended overall survival (OS) by 57% compared with ofatumumab in patients with relapsed or refractory chronic lymphocytic leukemia (CLL).
Read More
Considering the Discontinuation of Statins in Late-Stage Cancer Patients
May 31st 2014Patients starting palliative care for advanced cancer are often already on repeat prescriptions of statins to lower cholesterol and reduce risk of a heart attack or stroke, and many of these patients continue on statin therapy until death.
Read More
Obesity Increases Death Risk from Breast Cancer in Premenopausal Women with ER+ Disease
May 15th 2014Obesity significantly increases the risk of dying of breast cancer in premenopausal women with ER-positive early disease, according to findings from a large, retrospective study involving 80,000 patients.
Read More
Study Suggests Delaying ADT Until Symptoms Appear Following Primary Prostate Cancer Treatment
May 15th 2014A rising prostate-specific antigen (PSA) after surgery or radiation therapy for prostate cancer is not enough reason, on its own, to initiate androgen-deprivation therapy (ADT), a large observational study has found.
Read More